1. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, Rieken M, Speakman MJ, Tikkinen KAO, Karavitakis M, Kyriazis I, Malde S, Sakalis VI. Management of non-neurogenic male LUTS. EAU guidelines. ISBN 978-94-92671-07-3. 2020. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/. Accessed 25 May 2020
2. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE, Gonzalez CM, Kaplan SA, Penson DR (2010) Management of benign prostatic hyperplasia [Internet]. American Urological Association. https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014)#x3695. Accessed 25 May 2020
3. (2019) 2019 surveillance of lower urinary tract symptoms in men: management (NICE guideline CG97) [Internet]. National Institute for Health and Care Excellence (UK), London. https://www.ncbi.nlm.nih.gov/books/NBK552248/. Accessed 25 May 2020
4. Keehn A, Taylor J, Lowe FC (2016) Phytotherapy for benign prostatic hyperplasia. CurrUrol Rep 17(7):53
5. Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ (2012) Serenoarepens for benign prostatic hyperplasia. Cochrane Database. Syst Rev 12:CD001423